BioInvent International AB (fra:BIX0) Share Price

Company Profile

Business description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Contact
Ideongatan 1
LundSE-223 70
SWE
T: +46 462868550
E: [email protected]
https://www.bioinvent.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
109

Recommended

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Tyger Fitzpatrick | 06 March 2026

How the most traded shares stack up against our analysts views.

Tyger Fitzpatrick | 04 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,085.10	36.30	0.40%
CAC 40	7,993.49	52.31	-0.65%
DAX 40	23,591.03	224.72	-0.94%
Dow JONES (US)	47,436.65	518.09	-1.08%
FTSE 100	10,284.75	129.19	-1.24%
HKSE	25,757.29	435.95	1.72%
NASDAQ	22,356.82	392.16	-1.72%
Nikkei 225	55,620.84	342.78	0.62%
NZX 50 Index	13,519.35	98.54	-0.72%
S&P 500	6,732.40	98.31	-1.44%
S&P/ASX 200	8,851.00	25.80	0.29%
SSE Composite Index	4,124.19	15.63	0.38%